About this episode

Dr. Joshua Reuss discusses updates to the living guideline on stage IV NSCLC with driver alterations, focusing on new treatment strategies and clinical trial results.

Dr. Joshua Reuss returns to the podcast to discuss the update to the living guideline on stage IV NSCLC with driver alterations. The conversation focuses on new cancer treatment strategies for patients with advanced NSCLC and EGFR mutations, including classical EGFR alterations (exon 19 deletions, exon 21 L858R substitution) and rarer alterations (exon 20 insertion mutations). Dr. Reuss discusses results from clinical trials, including MARIPOSA and CHRYSALIS-2 and how these impacted first-line and subsequent line treatment recommendations. He looks to the future on what new evidence and potential updates are in the pipeline for this living guideline. Read the full living guideline " Therapy for Stage IV Non-Small Cell Lung Cancer with Driver Alterations, ASCO Living Guideline Version 2026.3.1 " LINK TO FULL TRANSCRIPT

People in this episode

Guest: Dr. Joshua Reuss

Topics covered

• NSCLC
• driver alterations
• cancer treatment strategies
• EGFR mutations
• clinical trials
• living guideline update

Keywords

• NSCLC
• EGFR mutations
• driver alterations
• clinical trials
• cancer treatment
• living guideline

Mentioned in this episode

Organizations: American Society of Clinical Oncology

Books & works: Therapy for Stage IV Non-Small Cell Lung Cancer with Driver Alterations, ASCO Living Guideline Version 2026.3.1

More episodes of ASCO Guidelines

• Treatment of Multiple Myeloma: ASCO Living Guideline Update 2026.1.1 · June 29, 2026 · 18 min
• Circulating Tumor DNA Testing in Solid Tumors and Lymphoma Guideline · June 18, 2026 · 18 min
• Therapy for Stage IV NSCLC Without Driver Alterations: ASCO Living Guideline Update 2026.3.1 Part 1 · May 26, 2026 · 13 min

Explore listener stats, chart rankings, contacts and more on the ASCO Guidelines podcast page.